Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pamrevlumab + FOLFIRINOX
- Development stage
- Discontinued
- Lead developer
- FibroGen
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Pamrevlumab + FOLFIRINOX is a **combination drug regimen** used in clinical trials for the treatment of **locally advanced, unresectable pancreatic cancer** and metastatic pancreatic ductal adenocarcinoma. The regimen consists of **pamrevlumab**, a fully human monoclonal antibody that targets and inhibits **connective tissue growth factor (CTGF)**, combined with **FOLFIRINOX**, a chemotherapy regimen composed of **folinic acid (leucovorin)**, **fluorouracil (5-FU)**, **irinotecan**, and **oxaliplatin**. Pamrevlumab’s mechanism is to block CTGF, which is implicated in cancer progression and tissue fibrosis. FOLFIRINOX destroys rapidly-dividing cells through cytotoxic effects of its chemotherapeutics. Developed by **FibroGen**, this combination was investigated in Phase 3 trials (e.g., LAPIS, Precision Promise) but failed to significantly improve overall survival compared to placebo plus chemotherapy, leading to discontinuation of pamrevlumab’s development for pancreatic cancer[1][3][5][7].
- Other names
- pamrevlumabFG-3019FG3019FG 3019FOLFIRINOXFOLFOXIRI (for FOLFIRINOX)
02
Targets
TOP1 (DNA Topoisomerase I)CTGF (Connective tissue growth factor)DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on pamrevlumab + FOLFIRINOX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pamrevlumab + FOLFIRINOX.